HIM
EGRX

Hillsdale Investment Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Hillsdale Investment Management’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-33,665
Closed -$889K – 640
2022
Q3 		$889K Hold
33,665
– – 0.08% 174
2022
Q2 		$1.5M Buy
+33,665
New +$1.55M 0.12% 170

Other funds holding EGRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SGCIA
Smith Graham & Co Investment Advisors Houston, Texas $868M AUM 24.69% 1-Year Est. Return

Hillsdale Investment Management's EGRX Position: Q4 2022 in Review

Hillsdale Investment Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2022, closing a stake of 33,665 shares — an estimated $889K sold.

Hillsdale Investment Management first reported a position in EGRX in Q2 2022 and held it in 2 quarters. The position peaked at $1.5M in Q2 2022. 152 funds tracked by Wall St. Rank hold EGRX as of Q4 2022.

  • Hillsdale Investment Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Hillsdale Investment Management sold 33,665 Eagle Pharmaceuticals, Inc. shares in Q4 2022, an estimated $889K.
  • Hillsdale Investment Management first reported a position in Eagle Pharmaceuticals, Inc. in Q2 2022 and held it in 2 quarters.
  • Hillsdale Investment Management's Eagle Pharmaceuticals, Inc. position peaked at $1.5M in Q2 2022.
  • 152 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2022.

Based on Hillsdale Investment Management's 13F filing for Q4 2022, filed 13 Feb 2023.